BioAmber Inc fka BIOAQ

[Koan]

Every timeline prediction to date has been remarkably incorrect.
Every short term outcome prediction to date has been remarkably incorrect.
Every price prediction to date has been remarkably incorrect.

Such would be expected when predictions about BioAmber Inc. are being made from half-truths, repetitive propaganda-like rhetoric, faulty analysis, misunderstandings about parent companies and subsidiaries, and confusion about the nature of cross-border legal proceedings.

It is not enough to simply read PwC's monitor's reports or a single judgement from the Canadian courts. One must also understand that "BioAmber" is not being handled as a single entity with which simple, elementary-level blanket statements can apply.

There are three legal corporations:

1. BioAmber Inc. (US Parent company, i.e. where the shareholder's shares are)
2. BioAmber Sarnia Inc. (foreign subsidiary; BioAmber Inc. is both a creditor and a shareholder of this company)
3. BioAmber Canada Inc. (foreign subsidiary; BioAmber Inc. is a shareholder of this company)

The US Chapter 15 proceeding is not functioning and does not function to magically mash all three of these entities into one big ball to be handled in one fell swoop. Its current purpose is to recognize the CCAA as a FOREIGN MAIN PROCEEDING for administrative efficiency. It is in no way an alteration of BioAmber Inc.'s corporate structure.

CCAA remains open. The Discharge Certificate has not been issued. This is what BioAmber Inc. shareholders are waiting on ahead of next steps.

No doubt some shareholders will proceed forward by either selling, make an enquiry or filing a complaint with the OSB (Office of the Superintendent of Bankruptcy), or obtaining legal representation, as has been the case with a handful of shareholders and Crane LLP.

BioAmber Inc. shares and shareholders will remain intact.